920P Avelumab (anti-PD-L1) in patients with platinum-refractory/ineligible recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Results from a phase Ib cohort

Authors :: Dongli Zhou
Nicolas Penel
Alain C. Mita
Deborah Jean Lee Wong
Martin Gutierrez
Amaury Daste
Marcis Bajars
Damien Vansteene
K-W. Lee
Ani Sarkis Balmanoukian
Patrick Schöffski
Ulrich Keilholz
C. Le Tourneau
Michael S. Gordon
Swati Goel
M.R. Patel
Hans Juergen Grote
Joël Guigay
Source :: Annals of Oncology. 31:S664
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Anti pd 1
Hematology
Avelumab
Platinum resistance
Internal medicine
Cohort
medicine
Basal cell
In patient
Head and neck
business
medicine.drug

Full Text Access

Tools